Analysts’ Top Healthcare Picks: RETA, LOXO

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Reata Pharmaceuticals (NASDAQ: RETA) and Loxo Oncology (NASDAQ: LOXO) with bullish sentiments.

Reata Pharmaceuticals (NASDAQ: RETA)

Cowen & Co. analyst Ritu Baral assigned a Buy rating to Reata Pharmaceuticals (NASDAQ: RETA) today. The company’s shares opened today at $24.42.

Baral observed:

“RETA reported 3Q17 financials yesterday, noting that the three major programs.”

According to TipRanks.com, Baral is a top 100 analyst with an average return of 23.4% and a 51.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on Reata Pharmaceuticals is Strong Buy and the average price target is $52.40, representing an 114.6% upside.

In a report issued on November 6, Citigroup also maintained a Buy rating on the stock with a $78 price target.
Loxo Oncology (NASDAQ: LOXO)

In a report released today, Eric Schmidt from Cowen & Co. assigned a Buy rating to Loxo Oncology (NASDAQ: LOXO). The company’s shares opened today at $79.84.

Schmidt commented:

“Loxo signed a >$1B worldwide collaboration with Bayer to market TRK inhibitors.”

According to TipRanks.com, Schmidt is a top 100 analyst with an average return of 39.2% and a 59.8% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Adaptimmune Therapeutics.

Currently, the analyst consensus on Loxo Oncology is Strong Buy and the average price target is $111.83, representing a 40.1% upside.

In a report issued on November 2, Stifel Nicolaus also reiterated a Buy rating on the stock with a $104 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.